Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Ovalbumin 323-339 peptide (sequence ISQAVHAAHAEINEAGR) is a 17-amino-acid fragment derived from chicken ovalbumin (UniProt P01012, residues 323-339), serving as a prominent immunodominant epitope in immunology research. It functions primarily as a MHC class II-restricted T-cell epitope, binding to mouse H2-IAd (I-A^d) and eliciting CD4+ T-cell responses, with evidence of two distinct binding registers that produce different T-cell stimulations. This peptide is also recognized as a B-cell epitope by IgE antibodies, contributing to Th2-biased immune responses, immediate hypersensitivity, and models of lung inflammation mimicking allergic asthma in BALB/c mice. In experimental settings, it induces serum IgE, IL-4 production, and splenocyte proliferation comparable to intact ovalbumin, accounting for 25-35% of T-cell responses to ovalbumin in isolated cells. Widely used in T-cell assays (e.g., ELISPOT, tetramers), it aids studies of antigen processing, presentation by antigen-presenting cells, epitope mapping, and immune tolerance mechanisms, but it is not a therapeutic target like receptors or enzymes—instead, a model tool for allergy, autoimmunity, and vaccine research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ovalbumin 323-339 peptide (OVA 323-339).